

TEST CHANGE

Porphyrins and Porphobilinogen (PBG), Urine 2002181, PORUFPBGU

Specimen	Requirements:
Opcomici	ricquirericito.

Patient Preparation:

Collect: 24-hour or random urine. Refrigerate 24-hour specimens during

collection.

Specimen Preparation: Protect from light. Transfer 8 mL aliquot to an ARUP <u>amber</u>

<u>transport tube</u>Amber Transport Tube. (Min: 4 mL) Record total volume and collection time interval on transport tube and test

Effective Date: May 20, 2024

request form.

Transport Temperature: Frozen.

Unacceptable Conditions: Body fluids other than urine.

Remarks:

Stability: Ambient: Unacceptable; Refrigerated: 4 days; Frozen: 1 month

Methodology: Quantitative High Performance Liquid Chromatography

(HPLC)/lon Exchange Chromatography/Quantitative Spectrophotometry/Quantitative High Performance Liquid

Chromatography-Tandem Mass Spectrometry

Performed: <u>Sun-Sat Mon-Fri</u>

Reported: 2-5 days

Note: Urine porphyrins are useful for the evaluation of cutaneous

photosensitivity to exclude porphyria cutanea tarda (PCT). Urine porphobilinogen (PBG) is useful for the evaluation of neurologic and/or psychiatric symptoms to exclude acute porphyrias such as acute intermittent porphyria (AIP).

CPT Codes: 84120; 84110

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Results are normalized to creatinine concentration and reported as a ratio of amounts (micromoles of porphyrin/moles of creatinine).

Porphobilinogen (PBG), Urine



Results for random urine specimens are normalized to creatinine (CRT) concentration and reported as a ratio of amounts (millimoles of PBG/mole of creatinine).

Effective Date: May 20, 2024

Porphobilinogen (PBG) in a random urine specimen is used to evaluate an attack of acute porphyria. Slight increases in urinary PBG are associated with acute porphyrias other than acute intermittent porphyria (AIP) and may indicate a resolving or treated acute porphyria.

<u>Urinary PBG in excess of two times the upper reference limit is consistent with acute porphyria.</u>

Per 24h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation.

Per 24h calculations are provided to aid interpretation for collections with a duration of 24 hours and an average daily urine volume. For specimens with notable deviations in collection time or volume, ratios of analytes to a corresponding urine creatinine concentration may assist in result interpretation.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Test Number	Components	Reference Interval		
	Creatinine, Urine - per 24h			
		Age	Male (mg/d)	Female (mg/d)
		3-8 years	140-700	140-700
		9-12 years	300-1300	300-1300
		13-17 years	500-2300	400-1600
		18-50 years	1000-2500	700-1600
		51-80 years	800-2100	500-1400
		81 years and older	600-2000	400-1300
	Porphobilinogen <u>, (PBG)</u> , Urine - <u>ratio to</u> <u>CRT</u> per volume	0.0 <u>- 0.2 mmol/mol CRT</u> -8.8 μmol/L 0-4 μmol/mol CRT 0-2 μmol/mol CRT 0.4 <u>- 1.5</u> 0-11.0 μmol/d 0-6 μmol/mol CRT 0-14 μmol/mol CRT		
	Uroporphyrin - ratio to CRT			
	Heptacarboxylate - ratio to CRT			
	Porphobilinogen (PBG), Urine -per 24h			
	Coproporphyrin I - ratio to CRT			
	Coproporphyrin III - ratio to CRT			

HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.